- Home
- IGR vs ORIC Comparison
IGR vs ORIC Comparison
Compare IGR & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IGR | ORIC |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 719.1M | 837.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | IGR | ORIC |
|---|---|---|
| Price | $4.61 | $8.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $19.73 |
| AVG Volume (30 Days) | 581.6K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 13.93% | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.15 | $4.65 |
| 52 Week High | $5.37 | $14.93 |
Technical Indicators
Market Signals| Indicator | IGR | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 40.95 | 31.58 |
| Support Level | $4.49 | $7.90 |
| Resistance Level | $4.90 | $13.89 |
| Average True Range (ATR) | 0.08 | 0.50 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 4.17 | 4.87 |
Price Performance
Historical ComparisonAbout IGR CBRE Global Real Estate Income Fund of Beneficial Interest
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.